SGLT2 Inhibitors Produce Cardiorenal Benefits by Promoting Adaptive Cellular Reprogramming to Induce a State of Fasting Mimicry: A Paradigm Shift in Understanding Their Mechanism of Action-Reference-Cited by-同舟云学术

SGLT2 Inhibitors Produce Cardiorenal Benefits by Promoting Adaptive Cellular Reprogramming to Induce a State of Fasting Mimicry: A Paradigm Shift in Understanding Their Mechanism of Action

Published:2020-02-11 Issue:3 Volume:43 Page:508-511
ISSN:0149-5992
Container-title:Diabetes Care
language:en
Short-container-title:

Author:

Packer Milton¹²^ORCID

Affiliation:

1. Baylor Scott & White Heart and Vascular Institute, Baylor University Medical Center, Dallas, TX

2. Imperial College, London, U.K.

Publisher

American Diabetes Association

Subject

Advanced and Specialized Nursing,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://diabetesjournals.org/care/article-pdf/43/3/508/530727/dci190074.pdf

Reference50 articles.

1. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials;Zelniker;Lancet,2019

2. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis;Neuen,2019

3. Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction: the DEFINE-HF trial;Nassif;Circulation,2019

4. CV protection in the EMPA-REG OUTCOME trial: a “thrifty substrate” hypothesis;Ferrannini;Diabetes Care,2016

5. Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis;Mudaliar;Diabetes Care,2016

Cited by 164 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Revisiting the full blood count: Circulating blood cells and their role in coagulation;British Journal of Haematology;2024-08-07

2. State-of-the-Art-Review: Mechanisms of Action of SGLT2 Inhibitors and Clinical Implications;American Journal of Hypertension;2024-07-17

3. SGLT2 inhibitors attenuate endothelial to mesenchymal transition and cardiac fibroblast activation;Scientific Reports;2024-07-16

4. The potential anti-arrhythmic effect of SGLT2 inhibitors;Cardiovascular Diabetology;2024-07-15

5. The Off-Target Cardioprotective Mechanisms of Sodium–Glucose Cotransporter 2 Inhibitors: An Overview;International Journal of Molecular Sciences;2024-07-14